View article

Percutaneous coronary intervention (PCI) remains the cornerstone in the treatment of coronary artery disease. The recent introduction of bioresorbable vascular scaffold (BRS) technology has expanded our therapeutic options, providing the potential benefit of vessel uncaging, restoration of vasomotion and positive remodelling after complete scaffold bioresorption. Furthermore, late scaffold problems, as seen with metallic drug eluting stents (DES), such as (very) late stent thrombosis and neatherosclerosis, would in theory be avoided [1]. However, a higher incidence of early adverse events including early scaffold thrombosis have recently been observed following PCI with Absorb bioresorbable vascular scaffold (BVS, Abbot Vascular, Santa Clara, California) as compared to contemporary metallic DES, and accounts of (very) late scaffold failure ((V) LScF) including late and very late scaffold thrombosis are …